At the 17 th International Photodynamic Association World Congress in Boston, Massachusetts, the Tookad™ Early Prostate Cancer Clinical Trial Team was the recipient of the Inaugural Tayyaba Hasan ...

The National Institute for Health and Care Excellence has concluded that Steba Biotech’s Tookad is not cost-effective enough to be approved enough for NHS funding to treat prostate cancer. The ...

Please provide your email address to receive an email when new articles are posted on . An FDA advisory committee today voted 2-13 against recommending approval of padeliporfin di-potassium, a ...

Two Israeli researchers are shining a lethal glow on evasive cancers. Between April 2004 and February 2005, 28 men with prostate cancer showed up at three Canadian hospitals for one-time injections of ...

Cancer is among the scariest diagnosis a person can receive. According to the American Cancer Society's "Cancer Facts & Figures 2016" report, there were an estimated 1.69 million new cases of cancer ...

Steba Biotech, a privately-owned biotechnology company focused on the development of innovative and minimally invasive photodynamic therapies and systems to treat cancers, today announced that the ...

Citing what it called poor study design and lack of follow-up data, the FDA’s Oncologic Drugs Advisory Committee voted 13-2 against recommending approval of Steba Biotech SA’s NDA for Tookad ...

Scientists at the Weizmann Institute may have found the cure for prostate cancer, at least if it is caught in its early stages – via a drug that doctors inject into cancerous cells and treat with ...

Cancer is among the scariest diagnosis a person can receive. According to the American Cancer Society's "Cancer Facts & Figures 2016" report, there were an estimated 1.69 million new cases of cancer ...

The National Institute for Health and Care Excellence has concluded that Steba Biotech’s Tookad is not cost-effective enough to be approved enough for NHS funding to treat prostate cancer. The ...